Opendata, web and dolomites

GLYCANC

Matrix glycans as multifunctional pathogenesis factors and therapeutic targets in cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 GLYCANC project word cloud

Explore the words cloud of the GLYCANC project. It provides you a very rough idea of what is the project "GLYCANC" about.

extracellular    interactions    2011    stem    acts    dysregulated    deeper    integrins    modulate    modulation    elucidating    basis    expression    hampered    cell    gag    immune    carbohydrates    players    diverse    matrix    therapeutic    signals    gags    applicable    multiple    disease    aberrant    performing    survival    glycosaminoglycans    angiogenesis    niches    mortality    training    analysing    hypothesize    combined    antitumoral    besides    expertise    biomarkers    emerged    population    levels    integrate    hanahan    pharmacological    structural    rational    complexity    chemokines    microenvironment    structurally    itself    dependent    shown    progression    cells    aging    weinberg    anticancer    structures    function    transfer    attractive    cancer    glycanc    regulation    entities    micrornas    proteoglycans    hallmarks    tumor    pg    epigenetic    mechanisms    multitargeted    malignant    stroma    simultaneously    emerges    molecular    glycans    adhesion    underlying    extensive    pgs    glycan    methodology    surfaces    metastasis   

Project "GLYCANC" data sheet

The following table provides information about the project.

Coordinator
WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER 

Organization address
address: SCHLOSSPLATZ 2
city: MUENSTER
postcode: 48149
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website https://campus.uni-muenster.de/glycanc/start/
 Project website https://campus.uni-muenster.de/glycanc/projekt/forschung/
 Total cost 567˙000 €
 EC max contribution 567˙000 € (100%)
 Programme 1. H2020-EU.1.3.3. (Stimulating innovation by means of cross-fertilisation of knowledge)
 Code Call H2020-MSCA-RISE-2014
 Funding Scheme MSCA-RISE
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2019-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER DE (MUENSTER) coordinator 103˙500.00
2    UNIVERSITA DEGLI STUDI DELL'INSUBRIA IT (VARESE) participant 126˙000.00
3    PANEPISTIMIO PATRON EL (RIO PATRAS) participant 103˙500.00
4    SEMMELWEIS EGYETEM HU (BUDAPEST) participant 67˙500.00
5    "NATIONAL CENTER FOR SCIENTIFIC RESEARCH ""DEMOKRITOS""" EL (AGIA PARASKEVI) participant 45˙000.00
6    UNIVERSITE DE REIMS CHAMPAGNE-ARDENNE FR (REIMS) participant 45˙000.00
7    UPPSALA UNIVERSITET SE (UPPSALA) participant 45˙000.00
8    FIDIA FARMACEUTICI SPA IT (Abano Terme) participant 27˙000.00
9    SEREND-IP GMBH DE (MUENSTER) participant 4˙500.00
10    CAIRO UNIVERSITY EG (GIZA) partner 0.00
11    CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECNICAS (CONICET) AR (BUENOS AIRES) partner 0.00
12    EWHA WOMANS UNIVERSITY KR (Seoul) partner 0.00
13    UNIVERSIDADE FEDERAL DO RIO DE JANEIRO BR (RIO DE JANEIRO) partner 0.00

Mappa

 Project objective

Cancer is a leading cause of mortality within the aging European population. Therapeutic targeting is hampered by the complexity of the disease, which includes not only molecular changes within the tumor cell itself, but also within its microenvironment. Tumor angiogenesis, tumor-stroma interactions, interactions with immune cells, with the extracellular matrix and cancer stem cell niches allow for malignant cell survival and promote metastasis, the leading cause for cancer-associated mortality. Proteoglycans (PGs) and glycosaminoglycans (GAGs) – structurally diverse carbohydrates of the extracellular matrix and cell surfaces - have emerged as novel biomarkers and molecular players both within tumor cells and their microenvironment, as they integrate signals from growth factors, chemokines and integrins, and cell-cell as well as matrix adhesion. Importantly, their expression is dysregulated in numerous tumor entities, and has been shown to modulate each of the hallmarks of cancer as defined by Hanahan and Weinberg (Cell 2011). We hypothesize that dysregulated function of PGs and GAGs simultaneously affects all molecular steps towards cancer metastasis as a general principle applicable to multiple tumor entities. Pharmacological modulation of their function thus emerges as an attractive multitargeted antitumoral approach which simultaneously acts at multiple levels of disease progression. Besides providing extensive knowledge transfer and training for researchers, the combined expertise of the GLYCANC consortium aims at performing a detailed structural analysis of PG and GAG glycans in disease using state-of-the art methodology, analysing their regulation via epigenetic mechanisms and microRNAs, and elucidating molecular mechanisms underlying aberrant PG and GAG function. GLYCANC will lead to a deeper understanding of glycan structures and glycan-dependent mechanisms promoting cancer progression, providing the basis for rational multitargeted anticancer approaches.

 Work performed, outcomes and results:  advancements report(s) 

 Deliverables

List of deliverables.
Chemotherapeutic resistance Documents, reports 2020-01-28 11:49:34
In vitro analysis of microRNA-dependent Syndecan-1 regulation in IBC Documents, reports 2020-01-28 11:49:34
Mechanistic in vitro investigation of Syndecan-dependenttranscriptional activation Documents, reports 2020-01-28 11:49:34
Inhibitory effect of 4- MU in vivo Documents, reports 2020-01-28 11:49:34
Analysis of signaling pathways Documents, reports 2020-01-28 11:49:34
Methods for preprocessing and processing of spectral data Documents, reports 2020-01-28 11:49:34
In vitro functional assays in a novel 3D culture system Documents, reports 2020-01-28 11:49:33
Functional in vitro studies Documents, reports 2020-01-28 11:49:33
In vivo study on the premetastatic niche Documents, reports 2020-01-28 11:49:33
Immune cells in the microenvironment Documents, reports 2020-01-28 11:49:33
Angiogenesis regulators Documents, reports 2020-01-28 11:49:33
Nanostic analysis Documents, reports 2020-01-28 11:49:33
Role of Syndecan-1 oligomerization in FAK activation Documents, reports 2020-01-28 11:49:33
Proof of concept for in vivo Raman probes for diagnosis of melanoma in patients and application to tumor-associated macrophages Documents, reports 2020-01-28 11:49:34
Analysis of angiogenic factors in immunomodulatory cells Documents, reports 2020-01-28 11:49:33
3D culture Documents, reports 2020-01-28 11:49:33
Functional impact of miRNA-dependent PG and HAS regulation Documents, reports 2020-01-28 11:49:33
Microvascular density Documents, reports 2020-01-28 11:49:33
Role of PGs in TGFbeta induced EMT Documents, reports 2020-01-28 11:49:33
Therapeutic potential of Ascidian GAGs Documents, reports 2020-01-28 11:49:33
Characterization of HA molecular weight from tumor and control tissue of at least three in vivo mouse tumor models Documents, reports 2020-01-28 11:49:33
ChIP experiments Documents, reports 2020-01-28 11:49:33
Impact of conventional therapeutics on the premetastatic niche Documents, reports 2020-01-28 11:49:31
microRNA-regulation of Syndecan-1 in clinical IBC specimens Documents, reports 2020-01-28 11:49:29
In vitro study of the premetastatic niche Documents, reports 2020-01-28 11:49:31
Changes in EMT marker expression Documents, reports 2020-01-28 11:49:31
Impact of PGs and GAGs on premature senescence of cancer cells Documents, reports 2020-01-28 11:49:30
Characterization of HS disaccharide structure from 8 breast cancer cell lines with altered Syndecan-1, 3-O-HS sulfation and 2-O-HS sulfation Documents, reports 2020-01-28 11:49:29
Epigenetic HAS2 promoter regulation Documents, reports 2020-01-28 11:49:30
Workshop on epigenetic regulation Websites, patent fillings, videos etc. 2020-01-28 11:49:30
Workshop on PGs and GAGs in metastasis Websites, patent fillings, videos etc. 2020-01-28 11:49:31
Diagnostic value of Syndecan-1 in IBC Documents, reports 2020-01-28 11:49:31
In vivo model of hepatocarcinogenesis Documents, reports 2020-01-28 11:49:29
microRNA regulation of Glypican-1, Syndecan-2 and HAS1-3 in breast and colon cancer Documents, reports 2020-01-28 11:49:29
Flow cytometric analysis of SP and ALDH phenotype Documents, reports 2020-01-28 11:49:30
Standardized Protocol for Tissue Microarray Analysis by FTIR and RAMAN spectroscopy Documents, reports 2020-01-28 11:49:32
Evaluation of HA related enzyme expression Documents, reports 2020-01-28 11:49:31
Standardized protocol for FTIR and RAMAN spectroscopic analysis of GAGs in cells and conditioned media. Documents, reports 2020-01-28 11:49:30
Impact of PG/HA on DNA damage response Documents, reports 2020-01-28 11:49:30
qPCR analysis of angiogenic factors in tumors Documents, reports 2020-01-28 11:49:31
Flow cytometric and qPCR analysis of stem cell markers Documents, reports 2020-01-28 11:49:32
Correlation of GAG structure with clinicopathological parameters Documents, reports 2020-01-28 11:49:31
Proof of concept to determine GAGs composition in cancer stromal tissue Documents, reports 2020-01-28 11:49:32
Spectroscopic delineation of the expression of GAGs in mice lung metastatic nodules Documents, reports 2020-01-28 11:49:32
Establichment of GLYCANC Website Websites, patent fillings, videos etc. 2020-01-28 11:49:31
Spectroscopic delineation of the expression of GAGs in murine melanoma, and PG-manuipulated cancer cell lines Documents, reports 2020-01-28 11:49:31
Changes in invasive behaviour Documents, reports 2020-01-28 11:49:31
Analysis of glioblastoma cell line GAG structure Documents, reports 2020-01-28 11:49:31

Take a look to the deliverables list in detail:  detailed list of GLYCANC deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GLYCANC" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GLYCANC" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.3.)

LoGov (2019)

Local Government and the Changing Urban-Rural Interplay

Read More  

ASTROSTAT-II (2020)

Development of Novel Statistical Tools for the Analysis of Astronomical Data

Read More  

SOMPATY (2020)

Spectral Optimization: From Mathematics to Physics and Advanced Technology

Read More